Objective: To examine the effects of valproic acid (VPA) on Notch1 expression and cancer cell proliferation in medullary thyroid cancer (MTC) cells.
M edullary thyroid cancer (MTC) is a neuroendocrine malignancy that arises from the calcitonin-secreting parafollicular C cells of the thyroid gland. MTC is the third most common type of thyroid cancer, accounting for approximately 3% of all cases. 1 The natural history of MTC is characterized by early lymph node metastasis. 2 In advanced cases MTC can invade local structures such as the trachea and jugular vein, and metastasize to distant organs such as the liver, lungs, and bone. 3, 4 Surgery is potentially curative, but complete resection is often not possible due to widespread disease. Furthermore, conventional anticancer treatments such as external beam radiation and cytotoxic chemotherapy are ineffective in MTC. Therefore, new therapeutic approaches to MTC are needed.
We have previously reported that ectopic expression of Notch1 in MTC cells resulted in suppression of neuroendocrine tumor markers and inhibition of cancer cell growth. 5 These findings suggested that Notch1 activation is an attractive therapeutic target for MTC. Until recently, however, pharmacologic activators of Notch1 signaling have not been available.
Valproic acid (VPA) is a branched-chain fatty acid that has been used for decades in the treatment of patients with epilepsy, bipolar disorder, and other neuropsychiatric diseases. 6 In addition to other properties, VPA is a histone deacetylase (HDAC) inhibitor and is currently in clinical trials for various malignancies. Stockhausen and colleagues reported the ability of VPA to increase Notch1 protein levels in neuroblastoma cells. 7 We subsequently demonstrated that VPA treatment of carcinoid cancer cells resulted in Notch1 activation, decreased production of neuroendocrine tumor markers, and dose-dependent suppression of cancer cell proliferation. 8 Based on these findings, we hypothesized that VPA may also activate Notch1 signaling in MTC cells, with similar antitumor effects. In this study, we describe for the first time the effects of VPA on Notch1 signaling, neuroendocrine tumor marker expression, and cancer cell growth in human MTC cells.
METHODS

Cell Culture and Cell Proliferation Assay
Human MTC cells (TT) were obtained from American Type Culture Collection (Manassas, VA) and maintained as previously described. 5, 9 MTC cell proliferation was measured by the MTT (methylthiazolyldiphenyl-tetrazolium bromide; Sigma-Aldrich, St. Louis, MO) rapid colorimetric assay as previously described. 10 Briefly, cells were seeded in quadruplicate on 24-well plates and incubated for 24 hours under standard conditions. The cells were then treated with the HDAC inhibitors VPA (2-propylpentanoic acid; Sigma-Aldrich; 0 -5 mM) or trichostatin A (TSA; Sigma-Aldrich; 0 -50 nM), and incubated for up to 6 days. The MTT assay was performed every 2 days by replacing the standard medium with 250 L of serum-free medium containing MTT (0.5 mg/mL) and incubated at 37°C for 3 hours. After incubation, 750 L of dimethyl sulfoxide (DMSO; Sigma-Aldrich) was added to each well and mixed thoroughly. The plates were then measured at 540 nm using a spectrophotometer (Quant; Bio-Tek Instruments, Winooski, VT).
Western Blot Analysis
MTC cells were treated with VPA (0 -5 mM) or TSA (0 -50 nM) for 48 hours and whole cell lysates were prepared as previously described. 11 Total protein concentrations were quantified with a bicinchoninic acid assay kit (Pierce Biotechnology, Rockford, IL). Denatured cellular extracts were resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis, transferred onto nitrocellulose membranes (Schleicher and Schuell, Keene, NH), blocked in milk, and incubated with appropriate antibodies as previously described. 11 The following primary antibody dilutions were used: 1:1,000 for ASCL1 (BD Pharmingen, San Diego, CA), active/cleaved caspase-3 (Cell Signaling Technology, Beverly, MA), active/cleaved caspase-9 (Cell Signaling Technology), poly(ADP-ribose) polymerase (PARP; Cell Signaling Technology), chromogranin A (Invitrogen, Carlsbad, CA), and cyclin D1 (Cell Signaling Technology), 1:2,000 for p21 (Cell Signaling Technology) and p27 (Santa Cruz Biotechnology), and 1:10,000 for G3PDH (1:10,000, Trevigen, Gaithersburg, MD). Horseradish peroxidase conjugated goat antirabbit or goat antimouse secondary antibodies (Pierce Biotechnology) were used, depending on the source of the primary antibody. For visualization of the protein signal, Immunstar (Bio-Rad Laboratories, Hercules, CA) or Super-Signal West Femto (Pierce Biotechnology) kits were used, according to the manufacturer's instructions, and then the blots were exposed to x-ray films.
Calcitonin Enzyme-linked Immunosorbent Assay
An enzyme-linked immunosorbent assay (ELISA) kit (Invitrogen) was used to quantify the amount of calcitonin in MTC cells, as previously described. 5 MTC cells were treated with or without VPA (3 mM) for 48 hours, and cell lysates were used as the antigen source in a standard sandwich ELISA, per the manufacturer's instructions. Samples were analyzed in quadruplicate.
Apoptosis ELISA
Apoptosis was measured by the quantitation of cytosolic mono-and oligonucleosome-bound fragmented DNA by using an ELISA kit (Roche Applied Biosciences), according to the manufacturer's instructions. Briefly, MTC cells were treated with or without VPA (3 mM) for 48 hours, cell lysates were harvested, and the cytosolic fraction was isolated. The lysate was used as an antigen source in a standard sandwich ELISA, which consisted of a primary antihistone antibody and a secondary anti-DNA antibody coupled to peroxidase. Absorbance values were used to calculate the percentage of fragmentation in comparison to control, and all samples were measured in triplicate.
Statistical Analysis
Analysis of variance (ANOVA) with Bonferroni post hoc testing (SPSS software, version 10.0; SPSS Inc., Chicago, IL) was used for statistical comparisons. A P value of Ͻ0.05 was considered to be statistically significant.
RESULTS
VPA Induces Notch1 Expression in MTC Cells
We have previously reported that Notch1 signaling is absent at baseline in human MTC tumors, and that Notch1 overexpression with an inducible Notch1 construct inhibited MTC cell growth and hormone production. 5 Recent research has demonstrated the ability of VPA to increase Notch1 protein levels in neuroblastoma 7 and carcinoid cancer 8 cells. Based on these findings, we performed Western blot analysis on extracts of VPA-treated MTC cells to determine if Notch1 signaling is activated by VPA. There was no detectable Notch1 protein in untreated cells. Importantly, VPA treatment resulted in induction of both full-length Notch1 and the active, cleaved form of the protein (Fig. 1 ). TSA, another HDAC inhibitor, also up-regulated expression of full-length and cleaved Notch1 (data not shown).
VPA Suppresses Neuroendocrine Tumor Markers and Hormones
ASCL1 is a helix-loop-helix transcription factor that regulates the neuroendocrine phenotype 12, 13 and is an estab- lished target of Notch1 signaling. 5, 14 Active Notch1 silences ASCL1 gene transcription and enhances ASCL1 protein degradation, leading to decreased levels of the protein. 15 At baseline, high levels of ASCL1 were present in MTC cells. However, treatment with VPA down-regulated ASCL1 protein expression ( Fig. 2 ). This suppression of ASCL1 provided further evidence that VPA activates Notch1 signaling in MTC cells. Patients with advanced MTC often suffer from debilitating symptoms because the tumors secrete various bioactive amines and peptides. Chromogranin A is an acidic glycoprotein that is cosecreted with hormones such as calcitonin by MTC cells. Chromogranin A is ubiquitously expressed in neuroendocrine tumors, and the protein is thus a useful clinical marker for this class of malignancies. As shown by Western analysis, untreated MTC cells had high levels of chromogranin A, whereas treatment with VPA dramatically suppressed the tumor marker ( Fig. 2) .
Calcitonin is a polypeptide hormone secreted by thyroid parafollicular C cells. Virtually all patients with MTC have elevated calcitonin, and measurement of the hormone has been used for screening of patients with hereditary MTC, diagnosis of MTC, and surveillance for disease recurrence after surgery. Interestingly, VPA treatment of MTC cells for 2 days resulted in a 23% decrease in intracellular calcitonin, as measured by ELISA (Fig. 3 ). This change in calcitonin was statistically significant. Taken together, these changes in ASCL1, chromogranin A, and calcitonin expression in MTC cells with VPA treatment indicate an alteration of the neuroendocrine phenotype.
VPA Inhibits MTC Cell Proliferation
After demonstrating that VPA activates Notch1 signaling and alters the neuroendocrine phenotype in MTC cells, we examined its effects on cell proliferation with the MTT assay. VPA treatment inhibited the growth of MTC cells in a dose-dependent manner (Fig. 4) . At a concentration as low as 1 mM, a statistically significant suppression of cancer cell growth was observed. Cells treated with VPA in concentra-tions of 2 mM and greater actually exhibited a progressive decrease in cell viability as measured by the MTT assay.
We assessed the ability of another HDAC inhibitor, TSA, to suppress growth of MTC cells. Similar to VPA, TSA inhibited MTC cell proliferation in a dose-dependent fashion ( Fig. 5 ), suggesting that MTC growth suppression may be a general property of HDAC inhibitors. 
VPA Induces Apoptosis In MTC Cells
Having established that VPA inhibits cell growth in MTC cells, we were interested in determining the mechanism of action for this effect. Previous studies have shown that VPA induces apoptosis or programmed cell death in a variety of cancers, including leukemia, 16, 17 multiple myeloma, 18 prostate cancer, 19, 20 cervical cancer, 21 thoracic cancer, 22 medulloblastoma, 23 melanoma, 24 and well-differentiated thyroid cancer. 25 We performed Western blot analysis to look for evidence of apoptosis in VPA-treated MTC cells.
The caspases are a family of proteases that mediate apoptosis. 26 Caspase-9 is the initiator caspase of the mitochondrial or intrinsic pathway, and caspase-3 is the common effector caspase of both the intrinsic and extrinsic apoptosis pathways. The DNA repair enzyme PARP is a target of active caspase-3, and PARP cleavage is a marker of apoptosis. Western blot analysis demonstrated an increase in active caspase-9 and caspase-3, as well as PARP cleavage, after VPA treatment of MTC cells (Fig. 6A) . We then used a cell death ELISA kit to confirm induction of apoptosis with VPA treatment. Compared with untreated control cells, MTC cells exposed to VPA for 2 days had a 14-fold increase in cytoplasmic histone-associated DNA fragments (Fig. 6B ), indicating apoptosis. We also performed immunoblot analysis to look for changes in mediators of cell cycle arrest, including p21, p27, and cyclin D1, but did not observe any significant changes in the expression of these proteins with VPA treatment (data not shown).
DISCUSSION
Notch1 signaling is minimal or absent in neuroendocrine tumors such as small cell lung cancer, 15, 27 carcinoid tumors, 8, 14, 28, 29 and medullary thyroid cancer, 5 suggesting that in these cancers Notch1 may act as a tumor suppressor. 30 Ectopic Notch1 expression in MTC cells, carcinoid tumor cells, and small cell lung cancer cells resulted in suppression of hormones and neuroendocrine tumor markers, and inhibition of cancer cell growth. 5, 27, 28 These findings led us to consider Notch1 activation an attractive target for the treatment of neuroendocrine tumors, including MTC. However, until recently, no small molecule Notch1 activators have been described.
Stockhausen and colleagues reported an increase in Notch1 protein after VPA treatment of neuroblastoma cells. 7 Based on this observation, we treated human gastrointestinal and pulmonary carcinoid cancer cell lines with VPA, and noted an increase in Notch1 signaling and inhibition of tumor cell growth in vitro. VPA also suppressed tumor growth in vivo, in a mouse xenograft model of carcinoid cancer. Importantly, the median peak serum VPA level in treated animals was well within the therapeutic range of human patients treated with VPA for epilepsy, indicating that it is possible to activate Notch1 and suppress neuroendocrine tumor growth with VPA at nontoxic concentrations. Notch1 gene knockdown with small interfering RNA (siRNA) blocked the inhibitory effects of VPA on carcinoid cancer cell growth and neuroendocrine tumor marker expression, providing further evidence to support the hypothesis that Notch1 is a crucial pathway for neuroendocrine tumorigenesis. 8 In the current study we report the results of VPA treatment of another type of neuroendocrine tumor, MTC. At baseline, Notch1 protein was essentially undetectable in MTC cells. VPA treatment resulted in an increase in both the full-length and cleaved, active form of Notch1. Furthermore, VPA suppressed levels of ASCL1, an established target of Notch signaling, as well as the neuroendocrine tumor marker chromogranin A, and the hormone calcitonin. These results are consistent with our previous findings in an inducible Notch1 model of MTC, where Notch1-mediated silencing of ASCL1 gene transcription down-regulated protein expression of chromogranin A and calcitonin. 5 The phenotypic change induced by VPA may have implications for the treatment and palliation of patients with advanced MTC disease, as these patients often suffer from endocrinopathies secondary to tumor secretion of hormones such as calcitonin.
The mechanism by which VPA activates Notch1 signaling is yet to be determined. VPA is known to inhibit HDAC enzymes. HDAC inhibitors increase histone acetylation, alter chromatin structure, and modulate gene transcription. 31 Several HDAC inhibitors including VPA and suberoylanilide hydroxamic acid have shown antineoplastic effects in a variety of cancers and are currently being evaluated in clinical trials. 32 The effects of HDAC inhibitors such as VPA in MTC and other neuroendocrine tumors may be mediated in part by activation of the Notch1 signaling pathway. 8, 33 VPA treatment of MTC cells resulted in dose-dependent inhibition of cancer cell proliferation. This effect was also seen after treatment of MTC cells with another HDAC inhibitor, trichostatin A. Western blot analysis revealed an increase in active caspase-9 and caspase-3, as well as PARP cleavage, indicating the induction of apoptosis after VPA treatment. A cell death ELISA confirmed that the mechanism of VPA-induced growth inhibition in MTC cells is apoptosis. Notch1 is known to mediate apoptosis of neural progenitor cells during embryonic development. 34 The ability of VPA to activate apoptotic pathways in MTC cells may form the basis of a novel targeted therapy for this disease. As the drug has a proven safety profile in humans, a clinical trial of VPA in patients with advanced MTC could be initiated relatively quickly.
